article_id,citation
1,"Abrahamowicz AA, Ebinger J, Whelton SP, Commodore-Mensah Y, Yang E. Racial and Ethnic Disparities in Hypertension: Barriers and Opportunities to Improve Blood Pressure Control. Curr Cardiol Rep. 2023;25: 17–27. doi:10.1007/s11886-022-01826-x"
2,"Ahmad Z, Noel N, Rudd T, Nadelson C, Ott M, Wilkinson T, et al. Implementation of a pharmacist-led contraceptive prescribing service in a campus community pharmacy. JACCP JAm Coll Clin Pharm. 2022;5: 1479. doi:10.1002/jac5.1732"
3,"Ahmed A, Saqlain M, Tanveer M, Blebil AQ, Dujaili JA, Hasan SS. The impact of clinical pharmacist services on patient health outcomes in Pakistan: a systematic review. BMC Health Services Research. 2021;21: 1–14. doi:10.1186/s12913-021-06897-0"
4,"Ajay V, Tian M, Chen H, Wu Y, Li X, Dunzhu D, et al. A cluster-randomized controlled trial to evaluate the effects of a simplified cardiovascular management program in Tibet, China and Haryana, India: study design and rationale. BMC public health. 2014;14: 924. doi:10.1186/1471-2458-14-924"
5,"Akazawa M, Fukuoka K. Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis. BMC Health Services Research. 2013;13: 124–124. doi:10.1186/1472-6963-13-124"
6,"Alderman MH, Alderman MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Annals of Internal Medicine. 1993;119: 329–335. doi:10.7326/0003-4819-119-4-199308150-00013"
7,"Alfian S, Abdulah R, Denig P, van Boven J, Hak E. Targeted and tailored pharmacist-led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: study protocol of a cluster randomised controlled trial. BMJ open. 2020;10: e034507. doi:10.1136/bmjopen-2019-034507"
8,"Alicic RZ, Short RA, Corbett CL, Neumiller JJ, Gates BJ, Daratha KB, et al. Medication Intervention for Chronic Kidney Disease Patients Transitioning from Hospital to Home: Study Design and Baseline Characteristics. Am J Nephrol. 2016;44: 122–129. doi:10.1159/000447019"
9,"Allen J, Himmelfarb C, Szanton S, Bone L, Hill M, Levine D. COACH trial: a randomized controlled trial of nurse practitioner/community health worker cardiovascular disease risk reduction in urban community health centers: rationale and design. Contemporary clinical trials. 2011;32: 403‐411. doi:10.1016/j.cct.2011.01.001"
10,"Anderegg MD, Gums TH, Uribe L, Coffey CS, James PA, Carter BL. Physician-Pharmacist Collaborative Management: Narrowing the Socioeconomic Blood Pressure Gap. Hypertension. 2016;68: 1314–1320. doi:10.1161/HYPERTENSIONAHA.116.08043"
11,"Angalakuditi M, Edgell E, Beardsworth A, Buysman E, Bancroft T. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. J Med Econ. 2010;13: 393–402. doi:10.3111/13696998.2010.496694"
12,"Arbabi CN, DuBose J, Charlton-Ouw K, Starnes BW, Saqib N, Quiroga E, et al. Outcomes and practice patterns of medical management of blunt thoracic aortic injury from the Aortic Trauma Foundation global registry. J Vasc Surg. 2022;75: 625–631. doi:10.1016/j.jvs.2021.08.084"
13,"Ashjian EJ, Yoo A, Piette JD, Choe HM, Thompson AN. Implementation and barriers to uptake of interactive voice response technology aimed to improve blood pressure control at a large academic medical center. J Am Pharm Assoc (2003). 2019;59: S104-S109.e1. doi:10.1016/j.japh.2018.11.013"
14,"Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA: Journal of the American Medical Association. 1998;279: 1458–1462. doi:10.1001/jama.279.18.1458"
15,"Axon DR, Johnson M, Abeln B, Forbes S, Anderson EJ, Taylor AM, et al. An Academic-Community Collaboration to Deliver Medication Therapy Management (MTM) Services to Patients Living in Rural Counties of a Southwestern State in  the United States. J Pharm Pract. 2022;35: 691–700. doi:10.1177/08971900211000219"
16,"Axon RN, Nietert PJ, Egan BM. Antihypertensive medication prescribing patterns in a university teaching hospital. J Clin Hypertens (Greenwich). 2010;12: 246–252. doi:10.1111/j.1751-7176.2009.00254.x"
17,"Barton A, Okorodudu D, Bosworth H, Crowley M. Clinical Inertia in a Randomized Trial of Telemedicine-Based Chronic Disease Management: lessons Learned. Telemedicine journal and e-health. 2018;24: 742‐748. doi:10.1089/tmj.2017.0184"
18,"Basheti I, Tadros O, Aburuz S. Value of a Community-Based Medication Management Review Service in Jordan: a Prospective Randomized Controlled Study. Pharmacotherapy. 2016;36: 1075‐1086. doi:10.1002/phar.1833"
19,"Basudev N, Crosby-Nwaobi R, Thomas S, Chamley M, Murrells T, Forbes A. A prospective randomized controlled study of a virtual clinic integrating primary and specialist care for patients with Type 2 diabetes mellitus. Diabetic medicine. 2016;33: 768‐776. doi:10.1111/dme.12985"
20,"Beadles CA, Farley JF, Ellis AR, Lichstein JC, Morrissey JP, DuBard CA, et al. Do medical homes increase medication adherence for persons with multiple chronic conditions? Med Care. 2015;53: 168–176. doi:10.1097/MLR.0000000000000292"
21,"Beran M, Asche S, Bergdall A, Crabtree B, Green B, Groen S, et al. Key components of success in a randomized trial of blood pressure telemonitoring with medication therapy management pharmacists. Journal of the American Pharmacists Association : JAPhA. 2018;58: 614‐621. doi:10.1016/j.japh.2018.07.001"
22,"Bosworth HB, Powers BJ, Olsen MK, McCant F, Grubber J, Smith V, et al. Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. Arch Intern Med. 2011;171: 1173–1180. doi:10.1001/archinternmed.2011.276"
23,"Bray P, Cummings D, Morrissey S, Thompson D, Holbert D, Wilson K, et al. Improved outcomes in diabetes care for rural African Americans. Annals of family medicine. 2013;11: 145‐150. doi:10.1370/afm.1470"
24,"Brixner DI, Joish VN, Oderda GM, Avey SG, Hanson DM, Cannon HE. Effects of benefit design change across 5 disease states. American Journal of Managed Care. 2007;13: 370–376."
25,"Brody A, Rahman T, Reed B, Millis S, Ference B, Flack JM, et al. Safety and efficacy of antihypertensive prescription at emergency department discharge. Acad Emerg Med. 2015;22: 632–635. doi:10.1111/acem.12660"
26,"Brugts JJ, Danser AHJ, de Maat MPM, den Uil CA, Boersma E, Ferrari R, et al. Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. Current Opinion in Cardiology. 2008;23: 296–301. doi:10.1097/hco.0b013e3283007ba6"
27,"Brummel A, Lustig A, Westrich K, Evans MA, Plank GS, Penso J, et al. Best practices: improving patient outcomes and costs in an ACO through comprehensive medication therapy management. J Manag Care Spec Pharm. 2014;20: 1152–1158."
28,"Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. Journal of the American Pharmacists Association: JAPhA. 2008;48: 23–31. doi:10.1331/japha.2008.07140"
29,"Burger CD, Ozbay AB, Lazarus HM, Riehle E, Montejano LB, Lenhart G, et al. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. J Manag Care Spec Pharm. 2018;24: 834–842. doi:10.18553/jmcp.2018.17391"
30,"Campbell ML, Mathys ML. Pharmacologic options for the treatment of obesity. American Journal of Health-System Pharmacy. 2001;58: 1301–1308."
31,"Chang TE, Ritchey MD, Park S, Chang A, Odom EC, Durthaler J, et al. National Rates of Nonadherence to Antihypertensive Medications Among Insured Adults With Hypertension, 2015. Hypertension. 2019;74: 1324–1332. doi:10.1161/HYPERTENSIONAHA.119.13616"
32,"Charrois T, McAlister F, Cooney D, Lewanczuk R, Kolber M, Campbell N, et al. Improving hypertension management through pharmacist prescribing; the rural Alberta clinical trial in optimizing hypertension (Rural RxACTION): trial design and methods. Implementation science. 2011;6: 94. doi:10.1186/1748-5908-6-94"
33,"Chen S, Swallow E, Li N, Faust E, Kelley C, Xie J, et al. Economic benefits associated with beta blocker persistence in the treatment of hypertension: a retrospective database analysis. Curr Med Res Opin. 2015;31: 615–622. doi:10.1185/03007995.2015.1013624"
34,"Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US pharmacists’ effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010;48: 923–933. doi:10.1097/MLR.0b013e3181e57962"
35,"Choudhry NK, Fischer MA, Smith BF, Brill G, Girdish C, Matlin OS, et al. Five features of value-based insurance design plans were associated with higher rates of medication adherence. Health Aff (Millwood). 2014;33: 493–501. doi:10.1377/hlthaff.2013.0060"
36,"Choudhry N, Isaac T, Lauffenburger J, Gopalakrishnan C, Khan N, Lee M, et al. Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): a cluster-randomized pragmatic trial. American heart journal. 2016;180: 90‐97. doi:10.1016/j.ahj.2016.07.017"
37,"Coe AB, Choe HM, Diez HL, Rockey NG, Ashjian EJ, Dorsch MP, et al. Pharmacists providing care in statewide physician organizations: findings from the Michigan Pharmacists Transforming Care and Quality Collaborative. J Manag Care Spec Pharm. 2020;26: 1558–1566. doi:10.18553/jmcp.2020.26.12.1558"
38,"Cohen LB, Taveira TH, Khatana SAM, Dooley AG, Pirraglia PA, Wu W-C. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes. Diabetes Educ. 2011;37: 801–812. doi:10.1177/0145721711423980"
39,"Colvin NN, Mospan CM, Buxton JA, Waggett JD, Gillette C. Using Indian Health Service (IHS) counseling techniques in an independent community pharmacy to improve adherence rates among patients with diabetes,  hypertension, or hyperlipidemia. J Am Pharm Assoc (2003). 2018;58: S59-S63.e2. doi:10.1016/j.japh.2018.04.024"
40,"Comer D, Couto J, Aguiar R, Wu P, Elliott D. Using aggregated pharmacy claims to identify primary nonadherence. Am J Manag Care. 2015;21: e655-660."
41,"Connor SE, Snyder ME, Snyder ZJ, Steinmetz Pater K. Provision of clinical pharmacy services in two safety net provider settings. Pharm Pract. 2009;7: 94–99. doi:10.4321/S1886-36552009000200005"
42,"Cooke CE, Xing S, Lee HY, Belletti DA. You wrote the prescription, but will it get filled? J Fam Pract. 2011;60: 321–327."
43,"Cooney D, Moon H, Liu Y, Miller RT, Perzynski A, Watts B, et al. A pharmacist based intervention to improve the care of patients with CKD: a pragmatic, randomized, controlled trial. BMC Nephrol. 2015;16: 56. doi:10.1186/s12882-015-0052-2"
44,"Cooper S, Booth S, Gardner C. A medication therapy management program (MTMP) in an integrated healthcare delivery system kaiser permanente georgia region. J Am Geriatr Soc. 2010;58: S169–S170. doi:10.1111/j.1532-5415.2010.02850.x"
45,"Curtiss FR, Fry RN, Avey SG. Framework for pharmacy services quality improvement--a bridge to cross the quality chasm. Part I. The opportunity and the tool. J Manag Care Pharm. 2004;10: 60–78. doi:10.18553/jmcp.2004.10.1.60"
46,"Curtiss FR, Fry RN, Avey SG. Framework for pharmacy services quality improvement-a bridge to cross the quality chasm. J  Manag Care Spec Pharm. 2020;26: 798–816. doi:10.18553/jmcp.2020.26.7.798"
47,"de Miguel AG, Jiménez-García R, San Martín M, Gonzalez IF, Campo AV, Gonzalez JM, et al. Drug surveillance study of amlodipine in patients with hypertension not controlled with drug therapy: NORCON study. Current Therapeutic Research. 2000;61: 863–870."
48,"de Oliveira DR, Brummel AR, Miller DB. Medication Therapy Management: 10 Years of Experience in a Large Integrated Health Care System. J Manag Care Spec Pharm. 2020;26: 1057–1066. doi:10.18553/jmcp.2020.26.9.1057"
49,"de Souza WA, Yugar-Toledo JC, Bergsten-Mendes G, Sabha M, Moreno H Jr. Effect of pharmaceutical care on blood pressure control and health-related quality of life in patients with resistant hypertension. American Journal of Health-System Pharmacy. 2007;64: 1955–1961. doi:10.2146/ajhp060547"
50,"Degli Esposti L, Degli Esposti E, Valpiani G, Di Martino M, Saragoni S, Buda S, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clinical Therapeutics. 2002;24: 1347–1346. doi:10.1016/s0149-2918(02)80039-x"
51,"Devlin JW, Dasta JF, Kleinschmidt K, Roberts RJ, Lapointe M, Varon J, et al. Patterns of antihypertensive treatment in patients with acute severe hypertension from a nonneurologic cause: Studying the Treatment of Acute Hypertension (STAT)  registry. Pharmacotherapy. 2010;30: 1087–1096. doi:10.1592/phco.30.11.1087"
52,"Diamantidis C, Bosworth H, Oakes M, Davenport C, Pendergast J, Patel S, et al. Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD) study: protocol and baseline characteristics of a randomized controlled trial. Contemporary clinical trials. 2018;69: 28‐39. doi:10.1016/j.cct.2018.04.003"
53,"Done N, Roy AM, Yuan Y, Pizer SD, Rose AJ, Prentice JC. Guideline-concordant initiation of oral anticoagulant therapy for stroke prevention in older veterans with atrial fibrillation eligible for Medicare Part  D. Health Serv Res. 2019;54: 128–138. doi:10.1111/1475-6773.13079"
54,"Edelman D, Fredrickson S, Melnyk S, Coffman C, Jeffreys A, Datta S, et al. Medical clinics versus usual care for patients with both diabetes and hypertension: a randomized trial. Annals of internal medicine. 2010;152: 689‐696. doi:10.7326/0003-4819-152-11-201006010-00001"
55,"Egan BM, Li J, Wagner CS. Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines. Hypertension. 2016;68: 318–323. doi:10.1161/HYPERTENSIONAHA.116.07575"
56,"Engel-Nitz NM, Darkow T, Lau H. Antihypertensive medication changes and blood pressure goal achievement in a managed care population. J Hum Hypertens. 2010;24: 659–668. doi:10.1038/jhh.2010.2"
57,"Evans C, Eurich D, Taylor J, Blackburn D. The Collaborative Cardiovascular Risk Reduction in Primary Care (CCARP) study. Pharmacotherapy. 2010;30: 766‐775. doi:10.1592/phco.30.8.766"
58,"Ferdinand KC, Yadav K, Nasser SA, Clayton-Jeter HD, Lewin J, Cryer DR, et al. Disparities in hypertension and cardiovascular disease in blacks: The critical role of medication adherence. J Clin Hypertens (Greenwich). 2017;19: 1015–1024. doi:10.1111/jch.13089"
59,"Ferrara AL, Pacioni D, Di Fronzo V, Russo BF, Staiano L, Speranza E, et al. Lifestyle educational program strongly increases compliance to nonpharmacologic intervention in hypertensive patients: a 2-year follow-up study. Journal of Clinical Hypertension. 2012;14: 767–772. doi:10.1111/jch.12016"
60,"Fisher NDL, Fera LE, Dunning JR, Desai S, Matta L, Liquori V, et al. Development of an entirely remote, non-physician led hypertension management program. Clin Cardiol. 2019;42: 285–291. doi:10.1002/clc.23141"
61,"Fontil V, Bibbins-Domingo K, Kazi DS, Sidney S, Coxson PG, Khanna R, et al. Simulating Strategies for Improving Control of Hypertension Among Patients with Usual Source of Care in the United States: The Blood Pressure Control Model. J Gen Intern Med. 2015;30: 1147–1155. doi:10.1007/s11606-015-3231-8"
62,"Fontil V, Gupta R, Moise N, Chen E, Guzman D, McCulloch CE, et al. Adapting and Evaluating a Health System Intervention From Kaiser Permanente to Improve Hypertension Management and Control in a Large Network of Safety-Net  Clinics. Circ Cardiovasc Qual Outcomes. 2018;11: e004386. doi:10.1161/CIRCOUTCOMES.117.004386"
63,"Fortuna RJ, Nagel AK, Rose E, McCann R, Teeters JC, Quigley DD, et al. Effectiveness of a multidisciplinary intervention to improve hypertension control in an urban underserved practice. J Am Soc Hypertens. 2015;9: 966–974. doi:10.1016/j.jash.2015.10.004"
64,"Gatwood J, Hanley R, Moore JS, Hohmeier K. Community pharmacist led, employer-based wellness services: A pilot study. Res Social Adm Pharm. 2019;15: 615–618. doi:10.1016/j.sapharm.2018.06.008"
65,"Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. American Journal of Health-System Pharmacy. 2007;64: 1279–1283. doi:10.2146/ajhp060434"
66,Gilmer T. Costs of chronic disease management for newly insured adults. Med Care. 2011;49: e22-27. doi:10.1097/MLR.0b013e318215d280
67,"Giruzzi M, Giruzzi N, Gonzalez V, McKeirnan K. implementing Student Pharmacist- Led Health Outreach Events at Long-term Care Facilities in a Medically Underserved Community. Sr Care Pharm. 2021;36: 387–396. doi:10.4140/TCP.n.2021.387"
68,"Grant R, Ashburner J, Jernigan M, Chang J, Borowsky L, Chang Y, et al. Randomized trial of a health IT tool to support between-visit-based laboratory monitoring for chronic disease medication prescriptions. Journal of general internal medicine. 2015;30: 619‐625. doi:10.1007/s11606-014-3152-y"
69,"Gums TH, Uribe L, Vander Weg MW, James P, Coffey C, Carter BL. Pharmacist intervention for blood pressure control: medication intensification and adherence. J Am Soc Hypertens. 2015;9: 569–578. doi:10.1016/j.jash.2015.05.005"
70,"Haley W, Shawl F, Charles Sternbergh W, Turan T, Barrett K, Voeks J, et al. Non-Adherence to Antihypertensive Guidelines in Patients with Asymptomatic Carotid Stenosis. Journal of stroke and cerebrovascular diseases. 2021;30: 105918. doi:10.1016/j.jstrokecerebrovasdis.2021.105918"
71,"Haramiova Z, Stasko M, Hulin M, Tesar T, Kuzelova M, Morisky D. The effectiveness of daily SMS reminders in pharmaceutical care of older adults on improving patients’ adherence to antihypertensive medication (SPPA): study protocol for a randomized controlled trial. Trials. 2017;18: 334. doi:10.1186/s13063-017-2063-8"
72,"Hedegaard U, Kjeldsen L, Pottegård A, Henriksen J, Lambrechtsen J, Hangaard J, et al. Improving Medication Adherence in Patients with Hypertension: a Randomized Trial. American journal of medicine. 2015;128: 1351‐1361. doi:10.1016/j.amjmed.2015.08.011"
73,"Hedegaard U, Hallas J, Ravn-Nielsen LV, Kjeldsen LJ. Process- and patient-reported outcomes of a multifaceted medication adherence intervention for hypertensive patients in secondary care. Res Social Adm Pharm. 2016;12: 302–318. doi:10.1016/j.sapharm.2015.05.006"
74,"Heisler M, Hofer T, Schmittdiel J, Selby J, Klamerus M, Bosworth H, et al. Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster randomized, controlled pragmatic trial. Circulation. 2012;125: 2863‐2872. doi:10.1161/CIRCULATIONAHA.111.089169"
75,"Heisler M, Hofer TP, Klamerus ML, Schmittdiel J, Selby J, Hogan MM, et al. Study protocol: the Adherence and Intensification of Medications (AIM) study--a cluster randomized controlled effectiveness study. Trials. 2010;11: 95. doi:10.1186/1745-6215-11-95"
76,"Highland KB, Hull M, Pruett J, Elliott C, Tsang Y, Drake W. Baseline history of patients using selexipag for pulmonary arterial hypertension. Ther Adv Respir Dis. 2019;13: 1753466619843774. doi:10.1177/1753466619843774"
77,"Hill NS, Cawley MJ, Heggen-Peay CL. New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension. J Manag Care Spec Pharm. 2016;22: S3-21. doi:10.18553/jmcp.2016.22.3-a.s3"
78,"Hirsch JD, Steers N, Adler DS, Kuo GM, Morello CM, Megan Lang, et al. Primary Care-based, Pharmacist-physician Collaborative Medication-therapy Management of Hypertension: A Randomized, Pragmatic Trial. Clinical Therapeutics. 2014;36: 1244–1254. doi:10.1016/j.clinthera.2014.06.030"
79,"Ho PM, Lambert-Kerzner A, Carey EP, Fahdi IE, Bryson CL, Dee Melnyk S, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge : A randomized clinical trial. JAMA Intern Med. 2014;174: 186–193. doi:10.1001/jamainternmed.2013.12944"
80,Hockenberry B. Multiple drug therapy in the treatment of essential hypertension. Nursing Clinics of North America. 1991;26: 417–436.
81,"Houle SK, Chuck AW, Tsuyuki RT. Blood pressure kiosks for medication therapy management programs: Business opportunity for pharmacists. Journal of the American Pharmacists Association: JAPhA. 2012;52: 188–194. doi:10.1331/japha.2012.11217"
82,"Hunt LM, Kreiner M, Brody H. The changing face of chronic illness management in primary care: a qualitative study of underlying influences and unintended outcomes. Ann Fam Med. 2012;10: 452–460. doi:10.1370/afm.1380"
83,"Hussain T, Franz W, Brown E, Kan A, Okoye M, Dietz K, et al. The Role of Care Management as a Population Health Intervention to Address Disparities and Control Hypertension: A Quasi-Experimental Observational Study. Ethn Dis. 2016;26: 285–294. doi:10.18865/ed.26.3.285"
84,"Isetts BJ, Schondelmeyer SW, Artz MB, Lenarz LA, Heaton AH, Wadd WB, et al. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. Journal of the American Pharmacists Association: JAPhA. 2008;48: 203–211. doi:10.1331/JAPhA.2008.07108"
85,"Isetts BJ, Buffington DE, Carter BL, Smith M, Polgreen LA, James PA. Evaluation of Pharmacists’ Work in a Physician-Pharmacist Collaborative Model for the Management of Hypertension. Pharmacotherapy. 2016;36: 374–384. doi:10.1002/phar.1727"
86,"Ismail S, Al-Subhi A, Youssif E, Ahmed M, Almalki A, Seger DL, et al. Patient-centered Pharmacist Care in the Hemodialysis Unit: a quasi-experimental interrupted time series study. BMC Nephrology. 2019;20: 1–9. doi:10.1186/s12882-019-1577-6"
87,"Iyengar RN, Balagere DS, Henderson RR, LeFrancois AL, Rabbitt RM, Frazee SG. Association between dispensing channel and medication adherence among medicare beneficiaries taking medications to treat diabetes, high blood pressure, or high  blood cholesterol. J Manag Care Spec Pharm. 2014;20: 851–861. doi:10.18553/jmcp.2014.20.8.851"
88,"Iyengar RN, LeFrancois AL, Henderson RR, Rabbitt RM. Medication Nonadherence Among Medicare Beneficiaries with Comorbid Chronic Conditions: Influence of Pharmacy Dispensing Channel. J Manag Care Spec Pharm. 2016;22: 550–560. doi:10.18553/jmcp.2016.22.5.550"
89,"Jackson GL, Oddone EZ, Olsen MK, Powers BJ, Grubber JM, McCant F, et al. Racial differences in the effect of a telephone-delivered hypertension disease management program. J Gen Intern Med. 2012;27: 1682–1689. doi:10.1007/s11606-012-2138-x"
90,"Jacobs M, Sherry P, Taylor L, Amato M, Tataronis G, Cushing G. Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes (PAMPERED) study. Journal of the American Pharmacists Association : JAPhA. 2012;52: 613‐621. doi:10.1331/JAPhA.2012.10183"
91,"Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310: 699–705. doi:10.1001/jama.2013.108769"
92,"Jarvis H, Oprinovich S, Guthrie K. Implementation of a self-measured blood pressure program in a community pharmacy: A pilot study. Journal of the American Pharmacists Association: JAPhA. 2022;62: S41-S46.e1. doi:10.1016/j.japh.2021.10.032"
93,"Javaid Z, Imtiaz U, Khalid I, Saeed H, Khan R, Islam M, et al. A randomized control trial of primary care-based management of type 2 diabetes by a pharmacist in Pakistan. BMC health services research. 2019;19: 409. doi:10.1186/s12913-019-4274-z"
94,"Johnson M, Jastrzab R, Tate J, Johnson K, Hall-Lipsy E, Martin R, et al. Evaluation of an Academic-Community Partnership to Implement MTM Services in Rural Communities to Improve Pharmaceutical Care for Patients with Diabetes  and/or Hypertension. J Manag Care Spec Pharm. 2018;24: 132–141. doi:10.18553/jmcp.2018.24.2.132"
95,"Jokanovic N, Tan EC, Sudhakaran S, Kirkpatrick CM, Dooley MJ, Ryan-Atwood TE, et al. Pharmacist-led medication review in community settings: An overview of systematic reviews. Res Social Adm Pharm. 2017;13: 661–685. doi:10.1016/j.sapharm.2016.08.005"
96,"Joshi M, Pham CM, Deng H, Norton RM, Mathew S, Tilton JJ, et al. EE269 Long-Term Cost-Effectiveness of a Pharmacist-Led Medication Therapy Management Clinic (MTMC) for Type 2 Diabetes Management. Value Health. 2022;25: S386. doi:10.1016/j.jval.2022.04.516"
97,"Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV, et al. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Services Research. 2009;44: 1640–1661. doi:10.1111/j.1475-6773.2009.00989.x"
98,"Kerby T, Asche S, Maciosek M, O’Connor P, Sperl-Hillen J, Margolis K. Adherence to blood pressure telemonitoring in a cluster-randomized clinical trial. Journal of clinical hypertension (Greenwich, Conn). 2012;14: 668‐674. doi:10.1111/j.1751-7176.2012.00685.x"
99,"Kilbourne AM, Goodrich D, Miklowitz DJ, Austin K, Post EP, Bauer MS. Characteristics of patients with bipolar disorder managed in VA primary care or specialty mental health care settings. Psychiatr Serv. 2010;61: 500–507. doi:10.1176/ps.2010.61.5.500"
100,"Koenigsfeld CF, Horning KK, Logemann CD, Schmidt GA. Medication therapy management in the primary care setting: a pharmacist-based pay-for-performance project. J Pharm Pract. 2012;25: 89–95. doi:10.1177/0897190011416671"
101,"Kohok DD, Sico JJ, Baye F, Myers L, Coffing J, Kamalesh M, et al. Post-stroke hypertension control and receipt of health care services among veterans. J Clin Hypertens (Greenwich). 2018;20: 382–387. doi:10.1111/jch.13194"
102,"Kolanczyk DM, Borchert JS, Lempicki KA. Focus group describing simulation-based learning for cardiovascular topics in US colleges and schools of pharmacy. Curr Pharm Teach Learn. 2019;11: 1144–1151. doi:10.1016/j.cptl.2019.07.005"
103,"Kristeller J, Manning D. Demonstrating the value of an innovative transitionof-care pharmacy service with quality measures and a unique way of gauging significance of pharmacy interventions. J Am Pharm Assoc. 2018;58: e187. doi:10.1016/j.japh.2018.04.004"
104,"Krumme AA, Glynn RJ, Schneeweiss S, Gagne JJ, Dougherty JS, Brill G, et al. Medication Synchronization Programs Improve Adherence To Cardiovascular Medications And Health Care Use. Health Aff (Millwood). 2018;37: 125–133. doi:10.1377/hlthaff.2017.0881"
105,Kuehn BM. Barbershop-Based Care Dramatically Trims Blood Pressure. Circulation. 2018;137: 1861–1862. doi:10.1161/CIRCULATIONAHA.118.034990
106,"Kulchaitanaroaj P, Brooks J, Chaiyakunapruk N, Goedken A, Chrischilles E, Carter B. Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. Journal of hypertension. 2017;35: 178‐187. doi:10.1097/HJH.0000000000001126"
107,"Kulchaitanaroaj P, Carter B, Goedken A, Chrischilles E, Brooks J. Instrumental variable methods to assess quality of care the marginal effects of process-of-care on blood pressure change and treatment costs. Research in social & administrative pharmacy : RSAP. 2015;11: e69‐83. doi:10.1016/j.sapharm.2014.07.007"
108,"Kumar G, Virmani T, Pathak K, Alhalmi A. A Revolutionary Blueprint for Mitigation of Hypertension via Nanoemulsion. BioMed Research International. 2022; 1–12. doi:10.1155/2022/4109874"
109,"Ladhani N, Majumdar S, Johnson J, Tsuyuki R, Lewanczuk R, Spooner R, et al. Adding pharmacists to primary care teams reduces predicted long-term risk of cardiovascular events in type 2 diabetic patients without established cardiovascular disease: results from a randomized trial. Diabetic medicine. 2012;29: 1433‐1439. doi:10.1111/j.1464-5491.2012.03673.x"
110,"Lalonde L, Quintana-Bárcena P, Lord A, Bell R, Clément V, Daigneault A, et al. Community Pharmacist Training-and-Communication Network and Drug-Related Problems in Patients With CKD: a Multicenter, Cluster-Randomized, Controlled Trial. American journal of kidney diseases. 2017;70: 386‐396. doi:10.1053/j.ajkd.2017.05.008"
111,"Lambert-Kerzner A, Del Giacco EJ, Fahdi IE, Bryson CL, Melnyk SD, Bosworth HB, et al. Patient-centered adherence intervention after acute coronary syndrome hospitalization. Circ Cardiovasc Qual Outcomes. 2012;5: 571–576. doi:10.1161/CIRCOUTCOMES.111.962290"
112,"Lee JK, Grace KA, Taylor AJ, Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA: Journal of the American Medical Association. 2006;296: 2563–2571. doi:10.1001/jama.296.21.joc60162"
113,"Leslie RS, Gilmer T, Natarajan L, Hovell M. A Multichannel Medication Adherence Intervention Influences Patient and Prescriber Behavior. J Manag Care Spec Pharm. 2016;22: 526–538. doi:10.18553/jmcp.2016.22.5.526"
114,"Leslie RS, Tirado B, Patel BV, Rein PJ. Evaluation of an integrated adherence program aimed to increase Medicare Part D star rating measures. J Manag Care Spec Pharm. 2014;20: 1193–1203. doi:10.18553/jmcp.2014.20.12.1193"
115,"Li N, Song J, Zhang M, Lv X, Hua H, Chang Y. Impact of medication therapy management (MTM) service model on multi-morbidity (MMD) patients with hypertension: a pilot RCT. BMC geriatrics. 2023;23: 10. doi:10.1186/s12877-023-03725-4"
116,"Li P, McElligott S, Bergquist H, Schwartz JS, Doshi JA. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia. Ann Intern Med. 2012;156: 776–784, W-263, W-264, W-265, W-266, W-267, W-268, W-269. doi:10.7326/0003-4819-156-11-201206050-00004"
117,"Litke J, Spoutz L, Ahlstrom D, Perdew C, Llamas W, Erickson K. Impact of the clinical pharmacy specialist in telehealth primary care. Am J Health Syst Pharm. 2018;75: 982–986. doi:10.2146/ajhp170633"
118,"Liu X, Byrd JB, Rodriguez CJ. Use of physician-recommended non-pharmacological strategies for hypertension control among hypertensive patients. J Clin Hypertens (Greenwich). 2018;20: 518–527. doi:10.1111/jch.13203"
119,"López-Jaramillo P, Barbosa E, Molina DI, Sanchez R, Diaz M, Camacho PA, et al. Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. Journal of Hypertension. 2019;37: 1126–1147. doi:10.1097/HJH.0000000000002072"
120,"Lum ZK, Chang KL, Tsou KY-K, Tan JY, Wong CSM, Kok ZY, et al. Enhancing diabetes care with community pharmacist-involved collaborative care model: A multi-centre randomised controlled trial. Diabetes Research & Clinical Practice. 2022;185: N.PAG-N.PAG. doi:10.1016/j.diabres.2022.109238"
121,"Maeng DD, Graham J, Bogart M, Hao J, Wright EA. Impact of a pharmacist-led diabetes management on outcomes, utilization, and cost. Clin Outcomes Res. 2018;10: 551–562. doi:10.2147/CEOR.S174595"
122,"Magid DJ, Ho PM, Olson KL, Brand DW, Welch LK, Snow KE, et al. A multimodal blood pressure control intervention in 3 healthcare systems. Am J Manag Care. 2011;17: e96-103."
123,"Margolis KL, Kerby TJ, Asche SE, Bergdall AR, Maciosek MV, O’Connor PJ, et al. Design and rationale for Home Blood Pressure Telemonitoring and Case Management to Control Hypertension (HyperLink): a cluster randomized trial. Contemp Clin Trials. 2012;33: 794–803. doi:10.1016/j.cct.2012.03.014"
124,"Margolis K, Asche S, Bergdall A, Dehmer S, Groen S, Kadrmas H, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310: 46‐56. doi:10.1001/jama.2013.6549"
125,"Margolis K, Asche S, Bergdall A, Dehmer S, Maciosek M, Nyboer R, et al. A Successful Multifaceted Trial to Improve Hypertension Control in Primary Care: why Did it Work? Journal of general internal medicine. 2015;30: 1665‐1672. doi:10.1007/s11606-015-3355-x"
126,McAdam-Marx C. Economic implications with newer agents to reduce cardiovascular risk in diabetes. Am J Manag Care. 2018;24: S279–S285.
127,"McAlister F, Majumdar S, Padwal R, Fradette M, Thompson A, Buck B, et al. Case management for blood pressure and lipid level control after minor stroke: PREVENTION randomized controlled trial. CMAJ : Canadian Medical Association journal. 2014;186: 577‐584. doi:10.1503/cmaj.140053"
128,"McNaughton CD, Brown NJ, Rothman RL, Liu D, Kabagambe EK, Levy PD, et al. Systolic Blood Pressure and Biochemical Assessment of Adherence: A Cross-Sectional Analysis in the Emergency Department. Hypertension. 2017;70: 307–314. doi:10.1161/HYPERTENSIONAHA.117.09659"
129,"McNeil M. Metabolic Syndrome Monitoring: Efficacy of an Educational Intervention on Knowledge, Attitude and Monitoring Behaviors of Outpatient Psychiatric Providers...28th Annual Scientific Session, June 2-6, 2017, Baltimore, Maryland. Nursing Research. 2016;65: E38–E38. doi:10.1097/NNR.0000000000000152"
130,"Mehanna M, Wang Z, Gong Y, McDonough CW, Beitelshees AL, Gums JG, et al. Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. Am J Hypertens. 2019;32: 668–675. doi:10.1093/ajh/hpz022"
131,"MIGLIOZZI DR, ZULLO AR, COLLINS C, ELSAID KA. Achieving blood pressure control among renal transplant recipients by integrating electronic health technology and clinical pharmacy services. American Journal of Health-System Pharmacy. 2015;72: 1987–1992. doi:10.2146/ajhp140810"
132,"Mills KT, Peacock E, Chen J, Zimmerman A, Brooks K, He H, et al. Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control (IMPACTS): Rationale and design of a  cluster-randomized trial. Am Heart J. 2020;230: 13–24. doi:10.1016/j.ahj.2020.08.009"
133,"Min L, Cigolle CT, Bernstein SJ, Ward K, Moore TL, Ha J, et al. Diabetes care improvement in pharmacist- versus nurse-supported patient-centered medical homes. Am J Manag Care. 2017;23: e374–e381."
134,"Moffett BS, Penny DJ. Variability in Treatment of Post-coarctectomy Hypertension: A Multicenter Study. Pediatr Cardiol. 2016;37: 772–777. doi:10.1007/s00246-016-1349-z"
135,"Moise N, Schwartz J, Bring R, Shimbo D, Kronish IM. Antihypertensive drug class and adherence: an electronic monitoring study. Am J Hypertens. 2015;28: 717–721. doi:10.1093/ajh/hpu199"
136,"Monane M, Gurwitz JH, Bohn RL, Glynn RJ, Levin R, Monette J, et al. The impact of thiazide diuretics on the initiation of lipid-reducing agents in older people: a population-based analysis... presented, in part, at the 1995 Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, San Diego, California, March 1995. Journal of the American Geriatrics Society. 1997; 71–75."
137,"Moore GD, Kosirog ER, Vande Griend JP, Freund JE, Saseen JJ. Expansion of clinical pharmacist positions through sustainable funding. Am J Health Syst Pharm. 2018;75: 978–981. doi:10.2146/ajhp170285"
138,"Moreira GC, Cipullo JP, Martin JF, Ciorlia LA, Godoy MR, Cesarino CB, et al. Evaluation of the awareness, control and cost-effectiveness of hypertension treatment in a Brazilian city: populational study. Journal of Hypertension. 2009;27: 1900–1907. doi:10.1097/HJH.0b013e32832dd10f"
139,"Neto P, Marusic S, de Lyra Júnior D, Pilger D, Cruciol-Souza J, Gaeti W, et al. Effect of a 36-month pharmaceutical care program on the coronary heart disease risk in elderly diabetic and hypertensive patients. Journal of pharmacy & pharmaceutical sciences. 2011;14: 249‐263. doi:10.18433/j3259q"
140,"Newman TV, Hernandez I, Keyser D, San-Juan-Rodriguez A, Swart ECS, Shrank WH, et al. Optimizing the Role of Community Pharmacists in Managing the Health of Populations: Barriers, Facilitators, and Policy Recommendations. J Manag Care Spec Pharm. 2019;25: 995–1000. doi:10.18553/jmcp.2019.25.9.995"
141,"Nguyen T, Wong E, Ciummo F. Polypharmacy in Older Adults: Practical Applications Alongside a Patient Case. Journal for Nurse Practitioners. 2020;16: 205–209. doi:10.1016/j.nurpra.2019.11.017"
142,"Nichols-English GJ, Provost M, Koompalum D, Chen H, Athar M. Strategies for pharmacists in the implementation of diabetes mellitus management programs: New roles in primary and collaborative care. Dis Manage Health Outcomes. 2002;10: 783–803."
143,"Njonkou G, Gbadamosi K, Muhammad S, Chughtai I, Le G, Fabayo A, et al. Assessment of the Impact of Pharmacist-led Transitions of Care Services in a Primary Health Center. Hospital Pharmacy. 2021;56: 187–190. doi:10.1177/0018578719883805"
144,"Nuffer W, McCollum M, Ellis SL, Turner CJ. Further development of pharmacy student-facilitated diabetes management clinics. Am J Pharm Educ. 2012;76: 50. doi:10.5688/ajpe76350"
145,"O’Connell J, Reid M, Rockell J, Harty K, Perraillon M, Manson S. Patient Outcomes Associated With Utilization of Education, Case Management, and Advanced Practice Pharmacy Services by American Indian and Alaska Native Peoples  With Diabetes. Med Care. 2021;59: 477–486. doi:10.1097/MLR.0000000000001521"
146,"Obreli-Neto P, Marusic S, Guidoni C, Baldoni Ade O, Renovato R, Pilger D, et al. Economic evaluation of a pharmaceutical care program for elderly diabetic and hypertensive patients in primary health care: a 36-month randomized controlled clinical trial. Journal of managed care & specialty pharmacy. 2015;21: 66‐75. doi:10.18553/jmcp.2015.21.1.66"
147,"Ohkuma T, Jun M, Rodgers A, Cooper M, Glasziou P, Hamet P, et al. Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus. Hypertension (dallas, tex : 1979). 2019;73: 84‐91. doi:10.1161/HYPERTENSIONAHA.118.12060"
148,"Östbring M, Eriksson T, Petersson G, Hellström L. Effects of a pharmaceutical care intervention on clinical outcomes and patient adherence in coronary heart disease: the MIMeRiC randomized controlled trial. BMC cardiovascular disorders. 2021;21: 367. doi:10.1186/s12872-021-02178-0"
149,"Overwyk KJ, Dehmer SP, Roy K, Maciosek MV, Hong Y, Baker-Goering MM, et al. Modeling the Health and Budgetary Impacts of a Team-based Hypertension Care Intervention That Includes Pharmacists. Med Care. 2019;57: 882–889. doi:10.1097/MLR.0000000000001213"
150,"Owsley C, Rhodes LA, McGwin GJ, Mennemeyer ST, Bregantini M, Patel N, et al. Eye Care Quality and Accessibility Improvement in the Community (EQUALITY) for adults at risk for glaucoma: study rationale and design. Int J Equity Health. 2015;14: 135. doi:10.1186/s12939-015-0213-8"
151,"Oyetayo OO, James C, Martinez A, Roberson K, Talbert RL. The Hispanic Diabetes Management Program: Impact of community pharmacists on clinical outcomes. J Am Pharm Assoc (2003). 2011;51: 623–626. doi:10.1331/JAPhA.2011.09229"
152,"Palacio A, Chen J, Tamariz L, Garay SD, Li H, Carrasquillo O. Impact of a physician-led point of care medication delivery system on medication adherence. Am J Manag Care. 2016;22: e264-269."
153,"Park H, Adeyemi A, Wang W, Roane TE. Impact of a telephonic outreach program on medication adherence in Medicare Advantage Prescription Drug (MAPD) plan beneficiaries. J Am Pharm Assoc (2003). 2017;57: 62-66.e2. doi:10.1016/j.japh.2016.07.006"
154,"Patel RP, Taylor SD, Patel RP, Taylor SD. Factors affecting medication adherence in hypertensive patients. Annals of Pharmacotherapy. 2002;36: 40–45."
155,"Peasah SK, Hammonds T, Liu Y, Campbell V, Manolis C, Good CB. Economic assessment of changes to an existing medication therapy management program of a large regional health plan. J Manag Care Spec Pharm. 2021;27: 147–156. doi:10.18553/jmcp.2021.27.2.147"
156,"Pepper MJ, Mallory N, Coker TN, Chaki A, Sando KR. Pharmacists’ impact on improving outcomes in patients with type 2 diabetes mellitus. Diabetes Educ. 2012;38: 409–416. doi:10.1177/0145721712443291"
157,"Peralta C, Frigaard M, Rubinsky A, Rolon L, Lo L, Voora S, et al. Implementation of a pragmatic randomized trial of screening for chronic kidney disease to improve care among non-diabetic hypertensive veterans. BMC nephrology. 2017;18: 132. doi:10.1186/s12882-017-0541-6"
158,"Persell S, Eder M, Friesema E, Connor C, Rademaker A, French D, et al. EHR-based medication support and nurse-led medication therapy management: rationale and design for a three-arm clinic randomized trial. Journal of the American Heart Association. 2013;2: e000311. doi:10.1161/JAHA.113.000311"
159,"Persell S, Karmali K, Lazar D, Friesema E, Lee J, Rademaker A, et al. Effect of Electronic Health Record-Based Medication Support and Nurse-Led Medication Therapy Management on Hypertension and Medication Self-management: a Randomized Clinical Trial. JAMA internal medicine. 2018;178: 1069‐1077. doi:10.1001/jamainternmed.2018.2372"
160,"Petersen L, Simpson K, Pietz K, Urech T, Hysong S, Profit J, et al. Effects of individual physician-level and practice-level financial incentives on hypertension care: a randomized trial. JAMA. 2013;310: 1042‐1050. doi:10.1001/jama.2013.276303"
161,"Pinto S, Holl S. Improving access-to-care leads to optimal outcomes in pharmacist-led medication therapy management (MTM) program. Value Health. 2010;13: A82. doi:10.1016/S1098-3015(10)72387-1"
162,"Pinto SL, Kumar J, Partha G, Bechtol RA. Pharmacist-Provided Medication Therapy Management (MTM) Program Impacts Outcomes for Employees with Diabetes. Population Health Management. 2014;17: 21–27. doi:10.1089/pop.2012.0124"
163,"Planas L, Crosby K, Farmer K, Harrison D. Evaluation of a diabetes management program using selected HEDIS measures. Journal of the American Pharmacists Association : JAPhA. 2012;52: e130‐8. doi:10.1331/JAPhA.2012.11148"
164,"Porter AC, Fitzgibbon ML, Fischer MJ, Gallardo R, Berbaum ML, Lash JP, et al. Rationale and design of a patient-centered medical home intervention for patients with end-stage renal disease on hemodialysis. Contemp Clin Trials. 2015;42: 1–8. doi:10.1016/j.cct.2015.02.006"
165,"Prendergast H, Del Rios M, Petzel-Gimbar R, Garside D, Heinert S, Escobar-Schulz S, et al. A hypertension emergency department intervention aimed at decreasing disparities: design of a randomized clinical trial. Contemporary clinical trials. 2018;64: 1‐7. doi:10.1016/j.cct.2017.11.009"
166,"Quinones ME, Pio MY, Chow DH, Moss E, Hulstein JL, Boatright SM, et al. Impact of clinical pharmacy services on outcomes and costs for indigent patients with diabetes. Am J Manag Care. 2016;22: e147-152."
167,"Ramalho de Oliveira D, Brummel AR, Miller DB. Medication therapy management: 10 years of experience in a large integrated health care system. J Manag Care Pharm. 2010;16: 185–195. doi:10.18553/jmcp.2010.16.3.185"
168,"Rodis JL, Sevin A, Awad MH, Porter B, Glasgow K, Hornbeck Fox C, et al. Improving Chronic Disease Outcomes Through Medication Therapy Management in Federally Qualified Health Centers. Journal of Primary Care & Community Health. 2017;8: 324–331. doi:10.1177/2150131917701797"
169,"Rodriguez de Bittner M, Chirikov VV, Breunig IM, Zaghab RW, Shaya FT. Clinical effectiveness and cost savings in diabetes care, supported by pharmacist counselling. J Am Pharm Assoc (2003). 2017;57: 102-108.e4. doi:10.1016/j.japh.2016.08.010"
170,"Ross LA, Bloodworth LS, Brown MA, Malinowski SS, Crane R, Sutton V, et al. The Mississippi Delta Health Collaborative Medication Therapy Management Model: Public Health and Pharmacy Working Together to Improve Population Health in the  Mississippi Delta. Prev Chronic Dis. 2020;17: E108. doi:10.5888/pcd17.200063"
171,"Roustit M, Chaumais M, Chapuis C, Gairard-Dory A, Hadjadj C, Chanoine S, et al. Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial. International journal of clinical pharmacy. 2020;42: 1128‐1138. doi:10.1007/s11096-020-01047-8"
172,"Ryu R, Tran H, Bahjri K. Association of Sacubitril/Valsartan with Metabolic Parameters in Patients with Reduced Ejection Fraction Heart Failure at a Multidisciplinary Clinic. Metab Syndr Relat Disord. 2021;19: 115–118. doi:10.1089/met.2020.0100"
173,"Santolucito PA, Tighe DA, McManus DD, Yarzebski J, Lessard D, Gore JM, et al. Management and outcomes of renal disease and acute myocardial infarction. Am J Med. 2010;123: 847–855. doi:10.1016/j.amjmed.2010.04.025"
174,"Santschi V, Wuerzner G, Chiolero A, Burnand B, Schaller P, Cloutier L, et al. Team-based care for improving hypertension management among outpatients (TBC-HTA): study protocol for a pragmatic randomized controlled trial. BMC cardiovascular disorders. 2017;17: 39. doi:10.1186/s12872-017-0472-y"
175,"Schultz BG, Tilton J, Jun J, Scott-Horton T, Quach D, Touchette DR. Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management. Value Health. 2021;24: 522–529. doi:10.1016/j.jval.2020.10.008"
176,"Sease JM, Franklin MA, Gerrald KR. Pharmacist management of patients with diabetes mellitus enrolled in a rural free clinic. Am J Health Syst Pharm. 2013;70: 43–47. doi:10.2146/ajhp120221"
177,"Selak V, Elley C, Bullen C, Crengle S, Wadham A, Rafter N, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ (Clinical research ed). 2014;348: g3318. doi:10.1136/bmj.g3318"
178,"Shah SJ, Stafford RS. Current Trends of Hypertension Treatment in the United States. Am J Hypertens. 2017;30: 1008–1014. doi:10.1093/ajh/hpx085"
179,"Shane-McWhorter L, McAdam-Marx C, Lenert L, Petersen M, Woolsey S, Coursey JM, et al. Pharmacist-provided diabetes management and education via a telemonitoring program. J Am Pharm Assoc (2003). 2015;55: 516–526. doi:10.1331/JAPhA.2015.14285"
180,"Shirneshan E, Kyrychenko P, Matlin OS, Avila JP, Brennan TA, Shrank WH. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence. Journal of Clinical Pharmacy & Therapeutics. 2016;41: 64–69. doi:10.1111/jcpt.12349"
181,"Shujuan Zhao, Hongwei Zhao, Song Du, Yuhua Qin. The impact of clinical pharmacist support on patients receiving multi-drug therapy for coronary heart disease in China: a long-term follow-up study. European Journal of Hospital Pharmacy. 2015;22: 323–327. doi:10.1136/ejhpharm-2014-000632"
182,"Siaw M, Ko Y, Malone D, Tsou K, Lew Y, Foo D, et al. Impact of pharmacist-involved collaborative care on the clinical, humanistic and cost outcomes of high-risk patients with type 2 diabetes (IMPACT): a randomized controlled trial. Journal of clinical pharmacy and therapeutics. 2017;42: 475‐482. doi:10.1111/jcpt.12536"
183,"Simonson W, Han LF, Davidson HE. Hypertension treatment and outcomes in US nursing homes: results from the US National Nursing Home Survey. J Am Med Dir Assoc. 2011;12: 44–49. doi:10.1016/j.jamda.2010.02.009"
184,"Smith J, Hillman L, Drawz P. Pharmacist-based antihypertensive medication review and assignment of morning versus evening dosing of once-daily antihypertensive medications: a pilot study to assess feasibility and efficacy in chronic kidney disease patients. Clinical and experimental hypertension (New York, NY : 1993). 2018;40: 569‐573. doi:10.1080/10641963.2017.1411493"
185,"Smith S, Carris N, Dietrich E, Gums J, Uribe L, Coffey C, et al. Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension. Journal of the American Society of Hypertension : JASH. 2016;10: 307‐317. doi:10.1016/j.jash.2016.01.010"
186,"Smith SM, Hasan M, Huebschmann AG, Penaloza R, Schorr-Ratzlaff W, Sieja A, et al. Physician Acceptance of a Physician-Pharmacist Collaborative Treatment Model for Hypertension Management in Primary Care. J Clin Hypertens (Greenwich). 2015;17: 686–691. doi:10.1111/jch.12575"
187,"Soong K, Zlokas DA, Tyagi S, Hodes DZ, Gennari A, Ruby CM. Impact of a pharmacist as a member of an interprofessional team to identify and reduce medication related problems during transitions of care from skilled nursing facilities (SNFs) to home. Pharmacotherapy. 2011;31: 426e."
188,"St Peter WL, Sozio SM, Shafi T, Ephraim PL, Luly J, McDermott A, et al. Patterns in blood pressure medication use in US incident dialysis patients over the first 6 months. BMC Nephrol. 2013;14: 249. doi:10.1186/1471-2369-14-249"
189,"Stange D, Kriston L, von-Wolff A, Baehr M, Dartsch D. Reducing cardiovascular medication complexity in a German university hospital: effects of a structured pharmaceutical management intervention on adherence. Journal of managed care pharmacy. 2013;19: 396‐407. doi:10.18553/jmcp.2013.19.5.396"
190,"Steele KM, Ruisinger JF, Bates J, Prohaska ES, Melton BL, Hipp S. Home-Based Comprehensive Medication Reviews: Pharmacist’s Impact on Drug Therapy Problems in Geriatric Patients. Consult Pharm. 2016;31: 598–605. doi:10.4140/TCP.n.2016.598"
191,"Steve Tsang CC, Browning J, Todor L, Dougherty S, Hohmeier KC, Sam Li M, et al. Factors associated with medication nonadherence among Medicare low-income subsidy beneficiaries with diabetes, hypertension, and/or heart failure. J Manag Care Spec Pharm. 2021;27: 971–981. doi:10.18553/jmcp.2021.27.8.971"
192,"Sun T, Xu Y, Xie H, Ma Z, Wang Y. Intelligent personalized exercise prescription based on an ehealth promotion system to improve health outcomes of middle-aged and older adult community dwellers: pretest-posttest study. Journal of medical Internet research. 2021;23: e28221. doi:10.2196/28221"
193,"Svarstad BL, Kotchen JM, Shireman TI, Brown RL, Crawford SY, Mount JK, et al. Improving refill adherence and hypertension control in black patients: Wisconsin TEAM trial. J Am Pharm Assoc (2003). 2013;53: 520–529. doi:10.1331/JAPhA.2013.12246"
194,"Thompson H, Swander L, Cohen R, Lukazewski A, Bartholow T, Pesik M, et al. Hypertension-Focused Medication Therapy Management: A Collaborative Pilot Program Uniting Pharmacists, Public Health, and Health Insurers in Wisconsin. Prev Chronic Dis. 2020;17: E105. doi:10.5888/pcd17.200058"
195,"Tobari H, Arimoto T, Shimojo N, Yuhara K, Noda H, Yamagishi K, et al. Physician-pharmacist cooperation program for blood pressure control in patients with hypertension: a randomized-controlled trial. American journal of hypertension. 2010;23: 1144‐1152. doi:10.1038/ajh.2010.127"
196,"Townsend RR, Epstein M. Resistant Hypertension: Insights on Evaluation and Management in the Post-SPRINT (Systolic Blood Pressure Intervention Trial) Era. Hypertension. 2016;68: 1073–1080. doi:10.1161/HYPERTENSIONAHA.116.07316"
197,"Tuttle KR, Alicic RZ, Short RA, Neumiller JJ, Gates BJ, Daratha KB, et al. Medication therapy management after hospitalization in CKD: A randomized clinical trial. Clin J Am Soc Nephrol. 2018;13: 231–241. doi:10.2215/CJN.06790617"
198,"Vande Griend JP, Saseen JJ, Sullivan KJ, Anderson HD. Identifying patients likely to be referred for a clinical pharmacist intervention in a family medicine residency-training clinic. JACCP JAm Coll Clin Pharm. 2019;2: 131–136. doi:10.1002/jac5.1047"
199,"Varleta P, Acevedo M, Akel C, Salinas C, Navarrete C, García A, et al. Mobile phone text messaging improves antihypertensive drug adherence in the community. Journal of clinical hypertension (Greenwich, Conn). 2017;19: 1276‐1284. doi:10.1111/jch.13098"
200,Verme-Gibboney C. Oral angiotensin-converting-enzyme inhibitors. American Journal of Health-System Pharmacy. 1997;54: 2689–2703.
201,"Victor RG, Blyler CA, Li N, Lynch K, Moy NB, Rashid M, et al. Sustainability of Blood Pressure Reduction in Black Barbershops. Circulation. 2019;139: 10–19. doi:10.1161/CIRCULATIONAHA.118.038165"
202,"Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock S, Wines RCM, et al. Closing the quality gap: revisiting the state of the science (vol. 4: medication adherence interventions: comparative effectiveness). Evid Rep Technol Assess (Full Rep). 2012; 1–685."
203,"Von Korff M, Katon WJ, Lin EHB, Ciechanowski P, Peterson D, Ludman EJ, et al. Functional outcomes of multi-condition collaborative care and successful ageing: results of randomised trial. BMJ. 2011;343: d6612. doi:10.1136/bmj.d6612"
204,"Wassertheil-Smoller S, Blaufox MD, Oberman A, Davis BR, Swencionis C, Knerr MO, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Annals of Internal Medicine. 1991;114: 613–620. doi:10.7326/0003-4819-114-8-613"
205,"Wehling M, Burkhardt H, Kuhn-Thiel A, Pazan F, Throm C, Weiss C, et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age and ageing. 2016;45: 262‐267. doi:10.1093/ageing/afv200"
206,"Wentzlaff D, Carter B, Ardery G, Franciscus C, Doucette W, Chrischilles E, et al. Sustained Blood Pressure Control Following Discontinuation of a Pharmacist Intervention. Journal of clinical hypertension (Greenwich, Conn). 2011;13: 431‐437. doi:10.1111/j.1751-7176.2011.00435.x"
207,"Wertz D, Hou L, DeVries A, Dupclay LJ, McGowan F, Malinowski B, et al. Clinical and economic outcomes of the Cincinnati Pharmacy Coaching Program for diabetes and hypertension. Manag Care. 2012;21: 44–54."
208,"Whalen E, Ely E, Brown A. The role of a multidisciplinary team in a pediatric pulmonary hypertension center. Pediatr Pulmonol. 2021;56: 630–635. doi:10.1002/ppul.24761"
209,"Wittayanukorn S, Westrick SC, Hansen RA, Billor N, Braxton-Lloyd K, Fox BI, et al. Evaluation of medication therapy management services for patients with cardiovascular disease in a self-insured employer health plan. J Manag Care Pharm. 2013;19: 385–395. doi:10.18553/jmcp.2013.19.5.385"
210,"Wu W-C, Taveira TH, Jeffery S, Jiang L, Tokuda L, Musial J, et al. Costs and effectiveness of pharmacist-led group medical visits for type-2 diabetes: A multi-center randomized controlled trial. PLoS One. 2018;13: e0195898. doi:10.1371/journal.pone.0195898"
211,"Yoon J, Wu F, Chang E. Impact of primary care intensive management on medication adherence and adjustments. Am J Manag Care. 2020;26: e239–e245. doi:10.37765/ajmc.2020.44073"
212,"Yu J, Shah BM, Ip EJ, Chan J. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern  California. J Manag Care Pharm. 2013;19: 102–114. doi:10.18553/jmcp.2013.19.2.102"
213,"Zeller A, Schroeder K, Peters TJ. Electronic pillboxes (MEMS) to assess the relationship between medication adherence and blood pressure control in primary care. Scandinavian Journal of Primary Health Care. 2007;25: 202–207. doi:10.1080/02813430701651954"
214,"Zhai P, Hayat K, Ji W, Li Q, Shi L, Atif N, et al. Efficacy of Text Messaging and Personal Consultation by Pharmacy Students Among Adults With Hypertension: Randomized Controlled Trial. Journal of Medical Internet Research. 2020;22: N.PAG-N.PAG. doi:10.2196/16019"
215,"Zhang D, Ritchey MR, Park C, Li J, Chapel J, Wang G. Association Between Medicaid Coverage and Income Status on Health Care Use and Costs Among Hypertensive Adults After Enactment of the Affordable Care Act. Am J Hypertens. 2019;32: 1030–1038. doi:10.1093/ajh/hpz101"
216,"Zullig L, Melnyk S, Stechuchak K, McCant F, Danus S, Oddone E, et al. The Cardiovascular Intervention Improvement Telemedicine Study (CITIES): rationale for a tailored behavioral and educational pharmacist-administered intervention for achieving cardiovascular disease risk reduction. Telemedicine journal and e-health. 2014;20: 135‐143. doi:10.1089/tmj.2013.0145"
217,"Zullig L, Stechuchak K, Goldstein K, Olsen M, McCant F, Danus S, et al. Patient-reported medication adherence barriers among patients with cardiovascular risk factors. Journal of managed care & specialty pharmacy. 2015;21: 479‐485. doi:10.18553/jmcp.2015.21.6.479"